AllSci News
Alloy Therapeutics and Institute for Protein Innovation partner on synthetic VHH antibody libraries
Alloy Therapeutics, a privately held biotechnology ecosystem company based in the United States, and the Institute for Protein Innovation (IPI), a Boston-based…
Diakonos Oncology’s DOC1021 dendritic cell therapy earns FDA Fast Track status for melanoma
Diakonos Oncology announced receipt of US FDA Fast Track Designation for DOC1021 (dubodencel), the company’s autologous double-loaded dendritic cell therapy, for the…
Kanvas Biosciences closes USD 48m Series A for microbiome cancer immunotherapy
Kanvas Biosciences, a spatial biology company headquartered in Princeton, New Jersey, has closed a USD 48 million Series A to advance its microbiome-based...
LTZ Therapeutics raises USD 38m for myeloid engager immunotherapy pipeline
LTZ Therapeutics, a clinical-stage immunotherapy company headquartered in Redwood City, California, has closed an oversubscribed USD 38 million financing...
Mount Sinai, Memorial Sloan Kettering explore colorectal cancer immune resistance with quadruple checkpoint combo
Researchers at the Icahn School of Medicine at Mount Sinai in New York, with contributions from Memorial Sloan Kettering Cancer Center, report that a...
CellCentric backed with USD 220m in Series D for myeloma hope inobrodib
Cambridge-based CellCentric has closed an oversubscribed USD 220 million Series D financing round to advance pivotal clinical development of inobrodib, its...
BioOra gains global CAR T-cell therapy rights from Wellington Zhaotai for Atla-cel development
BioOra Limited has signed a binding Heads of Terms agreement with Wellington Zhaotai Therapies Limited granting BioOra exclusive rights to develop and...
Avalo picks up USD 375m via share offering to support IL-1beta development
Wayne, Pennsylvania-based Avalo Therapeutics (Nasdaq: AVTX) announced the pricing of an underwritten public offering totaling USD 375 million in gross...
Hoth Therapeutics' HT-001 shows efficacy for EGFR inhibitor-associated dermatologic toxicities in Phase IIa trial
Hoth Therapeutics reported interim Phase IIa results for HT-001 in cancer patients experiencing EGFR inhibitor-associated dermatologic toxicities, according...
Kali Therapeutics' CD19 × CD3 bispecific T-cell engager KT502 ready for Phase I in rheumatoid arthritis
Kali Therapeutics has initiated a first-in-human Phase I trial of KT502, a CD19 × CD3 bispecific T-cell engager administered subcutaneously, in adults with...
Fosun/Teva's anti-PD-1/IL-2 fusion protein FXB0871 to enter the clinic in China for PD-(L)1-resistant solid tumors
A first-in-human (FIH) clinical trial of FXB0871 (TEV-56278), an anti-PD-1/IL-2 antibody-cytokine fusion protein, has been registered in China, with HKEX-...
Cenna Biosciences' amyloid beta-targeting peptide 8M2D enters Phase I/b trial for early Alzheimer's disease
Cenna Biosciences is moving its synthetic peptide 8M2D — also referred to as Nubytide™ in prior company disclosures and as P8 in earlier academic literature...
Epicrispr and Forge Biologics partner on AAV manufacturing for EPI-321 FSHD gene therapy
Epicrispr Biotechnologies and Forge Biologics have announced an AAV manufacturing partnership to support the clinical development of EPI-321, an investigational gene therapy…
Abivax raises USD 45m in share offering for royalty repurchase
France-based Abivax SA (Nasdaq/Euronext Paris: ABVX) announced the pricing of a USD 45 million (EUR 38.5 million) offering of American Depositary Shares to...
Signadori Bio closes EUR 11.1m seed extension to advance monocyte engineering platform
Paris-based Signadori Bio SAS has closed a EUR 11.1 million seed extension round to advance its in vivo monocyte engineering platform for solid tumours,...
The AllSci Brief
Free, systematic R&D and deal news. Daily.